Payment overview · 2025
General Payments
$326.59
15 reported records · 7 companies
Healthcare provider profile · identity verified
Nicolas Seth Dawson, MD
Allopathic & Osteopathic Physicians|Family Medicine · LANDRUM, SC · NPI 1679197891
Verified facts
What the public records show
CMS Open Payments records show Nicolas Seth Dawson, MD received $326.59 in general payments during 2025 across 15 reported records.
Astellas Pharma US Inc accounted for 34.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $112.30 | 34.4% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $98.42 | 30.1% | 5 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $39.12 | 12.0% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $21.29 | 6.5% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $19.33 | 5.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.12 | 5.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.01 | 5.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $326.59 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $112.30 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $67.87 | 4 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $39.12 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $30.55 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $30.55 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $21.29 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $19.33 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.12 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $18.01 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 34 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
47 | 15 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
34 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 368 | 117 |
| Lisinopril | Lisinopril | 354 | 109 |
| Atorvastatin Calcium | Atorvastatin Calcium | 350 | 112 |
| Levothyroxine Sodium | Levothyroxine Sodium | 333 | 98 |
| Lorazepam | Lorazepam | 319 | 54 |
| Losartan Potassium | Losartan Potassium | 259 | 84 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 258 | 98 |
| Alprazolam | Alprazolam | 235 | 34 |
| Gabapentin | Gabapentin | 222 | 55 |
| Pantoprazole Sodium | Pantoprazole Sodium | 215 | 72 |
| Furosemide | Furosemide | 208 | 64 |
| Zolpidem Tartrate | Zolpidem Tartrate | 198 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 193 | 55 |
| Metformin Hcl | Metformin Hcl | 177 | 62 |
| Omeprazole | Omeprazole | 163 | 57 |
| Meloxicam | Meloxicam | 160 | 43 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 157 | 33 |
| Potassium Chloride | Potassium Chloride | 150 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 147 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 145 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 140 | 47 |
| Metformin Hcl Er | Metformin Hcl | 138 | 41 |
| Tramadol Hcl | Tramadol Hcl | 136 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 134 | 28 |
| Sertraline Hcl | Sertraline Hcl | 129 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 128 | 49 |
| Simvastatin | Simvastatin | 125 | 41 |
| Pravastatin Sodium | Pravastatin Sodium | 124 | 33 |
| Tizanidine Hcl | Tizanidine Hcl | 123 | 40 |
| Trazodone Hcl | Trazodone Hcl | 123 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 119 | 39 |
| Eliquis | Apixaban | 105 | 28 |
| Carvedilol | Carvedilol | 101 | 37 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 98 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 97 | 27 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 94 | 19 |
| Glimepiride | Glimepiride | 92 | 26 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 89 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 86 | 27 |
| Ezetimibe | Ezetimibe | 82 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 81 | 22 |
| Alendronate Sodium | Alendronate Sodium | 79 | 25 |
| Famotidine | Famotidine | 79 | 21 |
| Ozempic | Semaglutide | 79 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 76 | 62 |
| Montelukast Sodium | Montelukast Sodium | 75 | 25 |
| Pregabalin | Pregabalin | 75 | 18 |
| Clonazepam | Clonazepam | 74 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 73 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 69 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 66 | 31 |
| Spironolactone | Spironolactone | 65 | 19 |
| Bupropion Xl | Bupropion Hcl | 64 | 15 |
| Allopurinol | Allopurinol | 61 | 15 |
| Celecoxib | Celecoxib | 59 | 14 |
| Cephalexin | Cephalexin | 59 | 50 |
| Estradiol | Estradiol | 59 | 21 |
| Meclizine Hcl | Meclizine Hcl | 59 | 21 |
| Prednisone | Prednisone | 59 | 40 |
| Donepezil Hcl | Donepezil Hcl | 56 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 56 | 21 |
| Azithromycin | Azithromycin | 54 | 45 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 54 | 43 |
| Warfarin Sodium | Warfarin Sodium | 53 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 50 | 19 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 50 | 13 |
| Fluconazole | Fluconazole | 50 | 29 |
| Glipizide Er | Glipizide | 49 | 15 |
| Xarelto | Rivaroxaban | 48 | suppressed |
| Nystatin | Nystatin | 47 | 27 |
| Synthroid | Levothyroxine Sodium | 47 | 15 |
| Mirtazapine | Mirtazapine | 44 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 43 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | 12 |
| Ipratropium Bromide | Ipratropium Bromide | 42 | 24 |
| Ondansetron Odt | Ondansetron | 42 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | suppressed |
| Temazepam | Temazepam | 38 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 35 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 35 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 35 | 14 |
| Jardiance | Empagliflozin | 34 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | 11 |
| Diazepam | Diazepam | 31 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | suppressed |
| Trulicity | Dulaglutide | 30 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 29 | 12 |
| Fenofibrate | Fenofibrate | 29 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 28 | suppressed |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 20 |
| Amiodarone Hcl | Amiodarone Hcl | 27 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 26 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 24 |
| Lansoprazole | Lansoprazole | 25 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 25 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Carbamazepine | Carbamazepine | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Naproxen | Naproxen | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Atenolol | Atenolol | 22 | suppressed |
| Glipizide | Glipizide | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 20 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Levofloxacin | Levofloxacin | 20 | 16 |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 17 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 17 | 17 |
| Mupirocin | Mupirocin | 17 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 11 |
| Klor-Con M10 | Potassium Chloride | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Dofetilide | Dofetilide | 15 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 13 |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Lubiprostone | Lubiprostone | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 11 |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 13 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 13 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 12 | 12 |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Ciclopirox | Ciclopirox | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Niacin Er | Niacin | 11 | suppressed |
| Oxycontin | Oxycodone Hcl | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $326.59 · 15 records | Astellas Pharma US Inc | INSPIRE, JARDIANCE, QULIPTA, SAPIEN 3 Ultra RESILIA, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, Veozah, WATCHMAN Access System | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error